ArticleDrug and alcohol review2025
Susceptibility to Hepatitis B Virus Infection Among People Who Inject Drugs in Montreal, Canada.
Article in Drug and alcohol review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionPeople who inject drugs are at elevated risk of hepatitis B virus (HBV) infection, which is preventable by vaccination. We examined susceptibility to HBV infection among a sample of people who inject drugs and live in Montreal, Canada.
methodsData were obtained from HEPCO, a prospective cohort study of people who had recently (within the past six months) injected drugs, between November 2022 and March 2024. The absence of hepatitis B surface antibody indicated susceptibility to HBV infection. These results were compared to self-report immune status. Logistic regression was used to identify factors associated with HBV susceptibility.
resultsOverall, 28.1% (108/384) of participants were susceptible to HBV infection. Over half (60.2%, 231/384) of participants correctly reported their immune status. Individuals born in Canada prior to the introduction of universal childhood vaccination programs had higher odds of susceptibility to HBV infection (adjusted odds ratio: 2.63, 95% confidence interval: 1.34-5.61), while those in opioid agonist treatment (0.60, 0.37-0.98) and with a history of hepatitis C infection (0.51, 0.32-0.83) had lower odds of HBV susceptibility. DISCUSSION AND
conclusionsAn important minority of people who inject drugs in Montreal remain susceptible to HBV infection. Moderate concordance between self-report and serological results indicates that serology or vaccine registry information should continue to be used to inform immunisation provision. People who inject drugs who were born prior to childhood vaccination programs and/or are not in opioid agonist treatment are subpopulations who require targeted interventions to increase vaccination coverage.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.